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Introduction
Migraine is a common disease that causes a great social
and economic burden [1]. There is evidence in the litera-
ture that migraineurs fare worse on healt-related quality of
life (HRQoL) than patients with other chronic diseases,
such as diabetes and hypertension [2] and that migraineurs
experience poorer quality of life even between attacks [3,
4]. The Global Burden of Disease Study [5] ranked severe
migraine in the highest disability class. The main goal of
migraine treatment has evolved from pain relief towards a
more comprehensive approach including preventing any
migraine symptoms as well as disability. Accordingly,
measuring only pain-related aspects such as number of
days with certain levels of pain, even though important,
may not suffice to understand some other elusive aspects
of migraine headache, some of them concerning the
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Abstract The purpose of our study
was to prospectively evaluate the
impact of preventive drug treatment
on the quality of life of patients
with episodic migraine (EM).
Quality of life evaluations can
enhance traditional measures of
therapeutic efficacy. Thirty-five
consecutive EM without aura
patients attending a tertiary care
unit (Batatais Headache Clinic)
entered the study. They were given
a prescription for preventive med-
ication and completed the validated
Portuguese version of the generic
instrument Short Form-36 (SF-36)
questionnaire. Six months later,
patients were given another SF-36.
We compared the pre-treatment and
post-treatment scores for the SF-36
and analysed the headache diaries.
The mean age of the 35 patients (32
women and 3 men) was 40.2 years
(range 18–60 years). All 35 patients
completed the pretreatment and fol-
low-up SF-36. The pre-treatment
and post-treatment mean frequency
of migraine attacks was 9.16 and
2.4 crises per month, respectively
(p<0.05). After the six months of
preventive treatment, six of the
eight domains evaluated by the SF-
36 (role physical, bodily pain, gen-
eral health, vitality, social function
and mental health) showed statisti-
cally significant (p<0.05) improve-
ment. The preventive treatment of
migraine leads to a significant
improvement in the quality of life
of patients with EM. This improve-
ment was measurable by the gener-
al quality of life instrument SF-36.
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attacks and others interictal symptoms. Measurements
using health-related quality of life (HRQoL) instruments
may provide some new insight into the issue. HRQoL rep-
resents the global effect of illness and its treatment on a
patient, as reported and judged by the patient [6]. This is
what distinguishes them from measures of disability [7].
Measurements of HRQoL offer a quantitative assessment
of an individual’s health status including the aggregate
burden imposed by specific health conditions such as
migraine headache. HRQoL has been assessed using two
categories of questionnaires: generic and disease specific.
Generic health status measures are those that purport to be
broadly applicable across types and severities of disease,
across different medical treatments or health interven-
tions, and across demographic and cultural subgroups.
Disease-specific measures are designed to assess specific
diagnostic or patient populations, often with the goal of
measuring responsiveness or ‘clinically’ important
changes [8]. Accordingly, HRQoL tools have been
increasingly accepted as an instrument for assessing ther-
apeutic efficacy and clinical outcome [9].
The pharmacological treatment of migraine may be
acute (abortive) and/or preventive (prophylactic). The
acute treatment should be able to effect fast and complete
relief of pain and the associated symptoms of migraine.
The goal of preventive therapy is to reduce the frequency,
duration and severity of migraine attacks. The choice of
preventive treatment depends on the individual drug’s
efficacy and side effects, the patient’s wants, needs and
response to prior treatment, and the presence of any
comorbid or coexistent disease. As for acute drugs and
their effects on HRQoL, many instruments have been suc-
cessfully applied, most of them developed by the pharma-
ceutical companies [10, 11]. On the other hand, papers
concerning preventive migraine therapy and HRQoL tests
are rarely seen in the literature. Diamond et al. [12] stud-
ied the impact of topiramate (TPM) treatment on HRQoL
using two subscales (role-physical and vitality) from the
Medical Outcomes Study Short-Form 36 and the
Migraine-Specific Quality-of-Life questionnaire (MSQ).
The authors enrolled 468 patients, allocated to 4 treatment
groups (placebo, TPM 50 mg/day, TPM 100 mg/day, TPM
200 mg/day), and made up the intent-to-treat population.
The MSQ Role-Restrictive and Role-Preventive subscales
were significantly improved at all TPM doses relative to
placebo, and a significant improvement was also shown in
the MSQ Emotional Function subscale at 100 or 200
mg/day TPM. The Short Form-36 Role-Physical subscale
was significantly improved in both the 100 and 200
mg/day groups. D’Amico et al. [13] evaluated the effect of
preventive treatment for migraine without aura using the
Italian versions of the Migraine Disability Assessment
Score (MIDAS) questionnaire and the SF-36 survey. After
a 2-month run-in period, they were given a prophylactic
treatment and re-evaluated after 3 months. Seventy-three
patients completed the study. The results showed signifi-
cant changes after treatment intervention for headache fre-
quency, number of symptomatic drugs and MIDAS score
and six scales of SF-36 (except physical function and gen-
eral health). In order to add new information to this issue,
we performed a study as follows.
Subjects and methods
Thirty-five consecutive episodic migraine (EM) without aura
(according to the IHS 1988 criteria) patients attending a tertiary
care unit (Batatais Headache Clinic) entered the study. Inclusion
criteria were: no previous preventive treatment, ages ranging
from 18 to 65 years, history of migraine for at least one year,
days with headache frequency from 2 to 14 per month, and, in
female patients, the use of an effective contraceptive method
was required. Patients with transformed migraine or who were
previously diagnosed with chronic diseases known to have influ-
ence on HRQoL tool scores such as depression, diabetes,
osteoarthritis, congestive heart failure, hypertension, angina,
myocardial infarction, asthma or chronic low back pain were
excluded. During the initial patient interview, a complete neuro-
logical exam was performed and the Portuguese validated ver-
sion of the generic instrument SF-36 questionnaire was complet-
ed [14]. Except for the introduction of the prophylactic treat-
ment, no other changes were made in the current migraine
abortive treatment. After the first visit, patients underwent
another evaluation 40 days later, and a third on day 90. In order
to assure compliance, we performed a telephone interview once
a week. Six months later (last evaluation), patients were again
given the SF-36. Pre-treatment and post-treatment variables
were compared.
Statistical methods
In order to ascertain if a given variable had a normal distribu-
tion, the Kolmorov-Smirnoff test was used. For comparisons
between pre- and post-treatment, data with normal distribution
were analysed with the t-test. The Wilcoxon test was used as a
non-parametric alternative.
Results
The mean age of the 35 patients (32 women and 3 men)
was 40.2 years (18–60). Fifteen patients were treated with
the combination of beta-adrenergic blockers and tricyclic
antidepressants (amitriptyline or nortriptyline), five
patients received the combination of flunarizine and beta-
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adrenergic blockers, three patients were given neurolep-
tics, three patients were given flunarizine, two patients
received the combination of tricyclic antidepressants plus
verapamil, two patients were treated with tricyclic antide-
pressants plus neuroleptics, two patients were given vera-
pamil and two received valproic acid. One patient was
treated with a combination of valproic acid and a neu-
roleptic. There was no modification of prescription due to
side effects. The pre-treatment and post-treatment mean
frequency of migraine attacks was 9.16 (SD: 3.45, range
3–14) and 2.4 (SD: 2.5, range 0–14) per month, respec-
tively (p<0.05). Six of eight domains evaluated by SF-36
(role physical, bodily pain, general health, vitality, social
function and mental health) showed statistically signifi-
cant (p<0.05) improvement (Table 1 and Fig. 1).
Discussion
Preventive medications are usually taken daily, whether or
not a headache attack is occurring, to reduce the frequen-
cy, duration or severity of attacks. The United States
Evidenced Based Guidelines for Migraine [15] has sug-
gested that circumstances that might warrant preventive
treatment include: (i) recurring migraine that significantly
interferes with the patient’s daily routine despite acute
treatment (e.g., two or more attacks a month that produce
disability that last for 3 days or headache attacks that are
infrequent but produce profound disability); (ii) failure of,
contraindication to, or troublesome side effects from acute
medication; (iii) overuse of acute medication; (iv) special
circumstances, such as hemiplegic migraine or attacks
with a risk of permanent neurological injury; (v) very fre-
quent headaches (more than two per week), or a pattern of
increasing attacks over time, with the risk of developing
rebound headache from acute attack medicine; or (vi)
patient preference, i.e., the desire to have as few acute
attacks as possible. The patients’ performance on HRQoL
tools has not yet been used to help the indication of pre-
ventive treatment.
Choosing the correct preventive drug or combination
is a complex task. In order to be more objective in the
process, Adelman et al. [16] proposed an analysis that
could be used to determine the cost-effectiveness of
migraine-preventive medications relative to selected
acute-care medications (called “cost-equivalent number”).
However, multiple factors can influence this decision,
such as patient’s age, gender, body weight, side effects of
the drug, and comorbid and coexisting diseases. This mat-
ter should be regarded as a joint venture between the doc-
tor and the patient, the person who is the real participant
in this “single-case scientific experiment” [17, 18]. Drug
combinations are commonly used for patients with refrac-
tory headache disorders [19] or for patients suffering from
some comorbid illness. Nevertheless, our point of view is
this approach can be used more frequently and is very use-
ful as the first step of a therapeutic plan in order to obtain
a more complete and fast response, such as we performed
in this research. Accordingly, some authors have suggest-
ed that a combination of drugs with distinct pathophysio-
logical mechanisms could enhance their efficacy [20].
Table 1 Comparison of the health scales before and after preven-
tive treatment. Data are mean (SD)
SF-36 domains Migraine After preventive 
treatment
Physical function 80 (19.8) 83 (15.6)
Role physical* 53.03 (41.8) 72.73 (38.7)
Bodily pain* 42 (26.5) 56.33 (23.7)
General health* 65.94 (22.4) 79.94 (20.2)
Vitality* 47.58 (19.3) 55.3 (23.2)
Social function* 61.36 (26.8) 72.35 (22.9)
Role emotional 54.44 (44.7) 62.63 (40.6)
Mental health* 56.36 (22.1) 66.18 (25.3)
*The variables of SF-36 with statistically significant (p<0.05) dif-
ferences
Fig. 1 Comparison of 36 health
scores in migraine patients before
and after preventive treatment
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How can we evaluate the efficacy of preventive migraine
treatment?
The recommendation of the IHS [21] states that evalua-
tion of efficacy should be based on the use of a headache
diary and the frequency of attacks per 4 weeks should be
the main parameter. Our sample experienced a significant
reduction of the frequency of attacks (9.16 to 2.4 in a six-
month follow-up, p<0.05). Despite this recommendation,
instruments for measuring HRQoL have been used by
some authors in order to incorporate additional informa-
tion. Dahlöf performed an open, prospective study in
order to evaluate the efficacy of abortive treatment with
sumatriptan on migraine patient’s socio-economic situa-
tion, subjective symptoms and general well-being [22].
Ninety-nine patients were included and followed for six
months and a significant improvement was observed for
the dimensions emotional distress, gastrointestinal symp-
toms and dizziness, whereas no significant change in the
patient’s general well-being between attacks, as evaluated
by the Minor Symptoms Evaluation Profile instrument,
could be demonstrated.
One of the HRQoL’s tools is the SF-36. The SF-36 is the
most widely used generic instrument for measuring
HRQoL. The instrument was developed by the Rand
Corporation to assess HRQoL in the Medical Outcomes
Study [23, 24] and was translated into numerous languages,
and the validity of the eight domains is confirmed in gener-
al populations and in a wide variety of patient groups in
more than two thousands articles. Solomon et al. [25] stud-
ied 147 migraine patients with abortive treatment with
sumatriptan and evaluated the effect of the treatment on the
HRQoL assessed by the SF-36. After six to nine months of
follow-up, the comparison of the pretreatment and the fol-
low-up SF-36 showed significant improvement of three
domains of the questionnaire: bodily pain, social function
and role functioning. Mushet et al. [26] reported significant
improvement of the score of the role emotional dimension
of the Short Form-36 after sumatriptan compared to usual
therapy. The results of this study showed that the majority
of the domains of SF-36 (except for physical function and
role emotional) improve with the intervention. The results
of this new study are perfectly compatible with the previous
observations of D’Amico et al. [13].
This open, longitudinal study aimed to evaluate if a
tailored preventive treatment, in a broad sense, could
modify some parameters of the quality of life of migraine
patients. We did not intend to make head-to-head drug
comparisons or to evaluate different drug dosages. The
trial was therefore not blinded or randomised, but rather
set up to mimic a clinical situation in which the patients
are found eligible for treatment with different drugs.
Because of the absence of a parallel placebo control
group, we could not completely exclude the interference
of some variables, such as the patient being seen at a ter-
tiary care centre [27]. It is likely, for example, that the
greater attention paid to the patients and the better under-
standing of the disease by expert physicians, when com-
pared with their previous experiences, have been per-
ceived positively by the patients and may affect treatment
results. There may be spontaneous headache remissions or
regression towards the mean on HRQoL measurements,
especially if patients choose to seek care for headache
when they are at their worst. We did not observe dropouts,
missed visits or withdrawals. The assessments were made
in a selected group of migraine patients recruited from a
special Headache Clinic, and so extrapolation of the
results to the whole migraine population should be treated
with caution.
The preventive medication treatment was used in order
to obtain the maximal clinical improvement, as we do in
clinical practice. The combination of drugs was used as
the first option in the majority of patients. Despite those
shortcomings, an important improvement in the quality of
life was found in our group of patients, giving support to
the current view that tailored treatment is a useful tool for
migraine management. Further studies are necessary to
confirm our findings.
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